Certificate of Analysis
QUALITY ASSURANCE TEST ONLY - Not for retail sale

Sample Name:

Kikoko - 5% Nano xx2426

Infused, Non-Inhalable

Date Issued:

10/07/2026

Sum Cannabinoids 50.254 mg/g
Total Cannabinoids 50.254 mg/g
Total THC 48.765 mg/g
Total CBD 0.118 mg/g

Sample Information

Sample Details

Sample ID:261006Q005

Batch Number:100626-KK-5%D

Cultivator / Manufacturer

Show Details

Distributor / Tested For

Show Details

Sampling Method: QSP 1265 - Sampling of Cannabis and Product Batches

Share

Easily share a link to this results page with your friends, followers, or business partners.

Cannabinoid Analysis - Summary

Sum of Cannabinoids: 50.254 mg/g

Total Cannabinoids: 50.254 mg/g

Total THC: 48.765 mg/g

Total CBD: 0.118 mg/g

Sum of Cannabinoids = Δ9-THC + THCa + CBD + CBDa + CBG + CBGa + THCV + THCVa + CBC + CBCa + CBDV + CBDVa + Δ8-THC + CBL + CBN

Total Cannabinoids = (Δ9-THC+0.877*THCa+Δ8-THC) + (CBD+0.877*CBDa) + (CBG+0.877*CBGa) + (THCV+0.877*THCVa) + (CBC+0.877*CBCa) + (CBDV+0.877*CBDVa) + CBL + CBN

Total THC/CBD is calculated using the following formulas to take into account the loss of a carboxyl group during the decarboxylation step:
Total THC = Δ9-THC + (THCa (0.877)) + Δ8-THC
Total CBD = CBD + (CBDa (0.877))

Sum of Cannabinoids: The concentration of each individual cannabinoid added together as they are, without accounting for decarboxylation. This measurement is of particular importance for certain cannabis products that are not intended to be heated prior to application or consumption.

Total Cannabinoids: The concentration of each acidic cannabinoid, multiplied by 0.877 to account for the loss of molecular mass that happens as it is converted to a neutral cannabinoid when heated. Then this calculated concentration is added to the concentrations of the corresponding neutral cannabinoid already present. This corrected data is of particular importance to both producers and consumers of products intended to be heated prior to application or consumption.

View Complete Test Results:

Tested by high-performance liquid chromatography with diode-array detection (HPLC-DAD).

Method: QSP 1157 - Analysis of Cannabinoids by HPLC-DAD

Summary

Total Cannabinoids: 50.254 mg/g

Total THC: 48.765 mg/g

(Δ9-THC+0.877*THCa+Δ8-THC)

Total CBD: 0.118 mg/g

(CBD+0.877*CBDa)

Total CBG: 0.467 mg/g

Total CBG (CBG+0.877*CBGa)

Total THCV: 0.329 mg/g

Total THCV (THCV+0.877*THCVa)

Total CBC: 0.215 mg/g

Total CBC (CBC+0.877*CBCa)

Total CBDV: ND

Total CBDV (CBDV+0.877*CBDVa)

Learn more

The cannabis plant contains dozens of active compounds called cannabinoids. These compounds are the primary contributors to the psychoactive effects of cannabis.

Cannabinoid testing determines the potency of a sample to aid in dosage considerations.

Cannabinoid Test Results

10/07/2026

Result Views

Swipe left on table to see additional columns

Compound LOD/LOQ
(mg/g)
Measurement
Uncertainty
(mg/g)
Result
(mg/g)
Result
(%)
Δ9 Tetrahydrocannabinol (Δ9THC) 0.002 / 0.014 ±2.6772 48.765 4.8765
Cannabigerol (CBG) 0.002 / 0.006 ±0.0226 0.467 0.0467
Tetrahydrocannabivarin (THCV) 0.002 / 0.012 ±0.0162 0.329 0.0329
Cannabinol (CBN) 0.001 / 0.007 ±0.0091 0.318 0.0318
Cannabichromene (CBC) 0.003 / 0.010 ±0.0069 0.215 0.0215
Cannabidiol (CBD) 0.004 / 0.011 ±0.0044 0.118 0.0118
Cannabicyclol (CBL) 0.003 / 0.010 ±0.0015 0.042 0.0042
Cannabichromenic Acid (CBCa) 0.001 / 0.015 N/A ND ND
Cannabidivarin (CBDV) 0.002 / 0.012 N/A ND ND
Cannabidiolic Acid (CBDa) 0.001 / 0.026 N/A ND ND
Cannabigerolic Acid (CBGa) 0.002 / 0.007 N/A ND ND
Tetrahydrocannabinolic Acid (THCa) 0.001 / 0.005 N/A ND ND
Cannabidivarinic Acid (CBDVa) 0.001 / 0.018 N/A ND ND
Tetrahydrocannabivarinic Acid (THCVa) 0.002 / 0.019 N/A ND ND
∆8 Tetrahydrocannabinol (Δ8THC) 0.01 / 0.02 N/A ND ND
SUM OF CANNABINOIDS 50.254 mg/g 5.0254%
Learn more

The cannabis plant contains dozens of active compounds called cannabinoids. These compounds are the primary contributors to the psychoactive effects of cannabis.

Cannabinoid testing determines the potency of a sample to aid in dosage considerations.

Your current browser is unsupported. Please install latest version of Firefox, Chrome or IE to view this site.